Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR -Mutated Lung Cancer | Zendy

Ken Suzawa | Zendy; Michael Offin | Zendy; Adam J. Schoenfeld | Zendy; Andrew J. Plodkowski | Zendy; Igor Odintsov | Zendy; Daniel Lu | Zendy; William W. Lockwood | Zendy; Maria E. Arcila | Zendy; Charles M. Rudin | Zendy; Alexander Drilon | Zendy; Helena A. Yu | Zendy; Gregory J. Riely | Zendy; Romel Somwar | Zendy; Marc Ladanyi | Zendy

Open Access

Acquired MET Exon 14 Alteration Drives Secondary Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in EGFR -Mutated Lung Cancer

Author(s) -

Ken Suzawa,

Michael Offin,

Adam J. Schoenfeld,

Andrew J. Plodkowski,

Igor Odintsov,

Daniel Lu,

William W. Lockwood,

Maria E. Arcila,

Charles M. Rudin,

Alexander Drilon,

Helena A. Yu,

Gregory J. Riely,

Romel Somwar,

Marc Ladanyi

Publication year - 2019

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.405

H-Index - 22

ISSN - 2473-4284

DOI - 10.1200/po.19.00011

Subject(s) - osimertinib , epidermal growth factor receptor , cancer research , crizotinib , kras , lung cancer , t790m , medicine , biology , egfr inhibitors , tyrosine kinase , erlotinib , cancer , afatinib , gefitinib , oncology , receptor , colorectal cancer , malignant pleural effusion

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research